From April to the end of December, net profit reached 66 million francs, after a loss of 157.5 million in the same period the previous year.
The investment company HBM Healthcare Investments confirmed on Monday the positive results for the first nine months of the staggered 2024-2025 financial year, provisionally published at the start of the year. Management highlighted a challenging macroeconomic environment.
From April to the end of December, net profit reached 66 million francs, after a loss of 157.5 million in the same period the previous year, according to the final quarterly report.
The net asset value (NAV) increased by 15% to 251.17 francs. In December, the company made a profit from the sale of Sai Life Sciences shares it held, leading to an increase in its NAV by 3.2% to 7.89 francs per share.
-Management particularly highlighted the performance of its unlisted companies and currency effects. Listed companies were slightly less profitable. In May, Yellow Jersey Therapeutics, then in the HBM Healthcare portfolio, was bought by the American giant Johnson & Johnson for $1.25 billion.
In terms of forecasts, management believes that in addition to the demanding market, China is weakened and the United States is preparing for a higher level of inflation in the medium term. For the health sector, “the situation will be clearer during the year 2025”, once American organizational uncertainties have dissipated.
Swiss
Related News :